Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore accelerating demand for NAD‑boosting products and validate Niagen’s transition from supplement leader to emerging pharmaceutical player, shaping the longevity‑health market.

Key Takeaways

• Revenue hits $31.1M, up 37% YoY
• Gross margin climbs to 65%, +480 bps
• Ingredient sales surge 135% YoY
• Over 800 clinics now offer Niagen Plus
• Parkinson’s NR trial completed, peer review pending

Pulse Analysis

The NAD‑precursor market has surged as consumers and clinicians seek evidence‑based anti‑aging solutions. Niagen Bioscience, the flagship brand behind TRU NIAGEN, leverages its patented nicotinamide riboside (NR) to dominate the supplement segment, while strategically positioning itself for pharmaceutical expansion. Recent media coverage and influencer partnerships have amplified brand awareness, translating into a 39% jump in e‑commerce sales and a robust pipeline of clinical studies that differentiate Niagen from generic competitors.

Financially, the quarter showcased disciplined scaling: revenue rose to $31.1 million, gross margin expanded to 65%—the highest in company history—and operating cash flow turned positive, delivering $9.1 million in the first half. The improved selling‑and‑marketing efficiency, now 26.4% of net sales, reflects a shift toward higher‑margin channels and a leaner cost structure. With $60.5 million of cash on hand and no debt, the firm is well‑positioned to fund its growth initiatives, while the raised guidance signals confidence in sustaining double‑digit top‑line momentum.

Beyond the balance sheet, Niagen’s clinical agenda could reshape its revenue mix. The completed phase‑three Parkinson’s trial and ongoing long‑COVID and ataxia telangiectasia programs signal a move toward prescription‑grade NR therapies, potentially unlocking higher‑margin pharmaceutical revenues. However, regulatory headwinds—such as the delayed NMN FDA response and scrutiny of 503B compounding practices—remain risks. Investors will watch how quickly Niagen can translate trial data into marketable drugs and whether its at‑home injection kit gains traction in the expanding telehealth ecosystem.